What we claim, and what we don't.
One
What eMazeBrain is built on
The platform rests on a set of propositions that are unremarkable in developmental practice and that you almost certainly already work from:
- Frequency matters. Short, frequent practice tends to produce more change than infrequent long practice, across most skill domains.
- Specificity matters. Training effects are largely specific to what is trained. Generic “brain fitness” is not a target; timing, inhibition and sustained attention are.
- Grading matters. Work that is too easy produces nothing and work that is too hard produces avoidance. The right difficulty is a moving target and needs adjusting.
- Adherence is the binding constraint. A well-designed program that is not completed produces nothing at all, and adherence is the variable that home programs most reliably fail on.
- Supervision matters. A clinician who can see what happened and adjust it is a materially different intervention from software a family runs unattended.
Those propositions are what the product is designed around: assessment-driven targeting, provider-set dosing, engagement as a delivery mechanism, and adherence made visible. They are design reasoning, not an outcome claim for this product, and we are not going to present them as one.
Two
Research in progress
A clinical study of the platform is under way. Until it reports, there is nothing here for us to show you, and a section of encouraging adjectives would be worse than an empty one.
Clinical study
Details of the study — institution, design, population, sample size, primary and secondary measures, and registration where applicable — will be published in this section, together with a link to the full paper once it is available.
Clinical practice data
Observational data from clinical use of the platform's approach exists but has not been released for publication. When it is, it will appear here described accurately — as clinic-observed data with its sample and limitations stated, not as a controlled trial.
If you are a researcher interested in studying the platform, or a clinic willing to contribute data to a study, get in touch.
Three
What we do not claim
This is the part most vendors leave out. It is also the part a credentialed reader trusts.
- We do not claim that eMazeBrain treats, mitigates or cures autism, ADHD or any learning disability.
- We do not claim it diagnoses anything. The assessment is a program-design instrument, not a diagnostic one.
- We do not claim it is a substitute for therapy, medication, or evaluation by a qualified clinician.
- We do not claim that improvements on our own measures transfer to academic, behavioural or functional outcomes. That is exactly the claim this category has historically over-reached on.
- We do not claim FDA clearance or authorisation. eMazeBrain is not marketed as a medical device.
- We do not publish outcome percentages we cannot source, and we do not have a testimonial saying something we could not say ourselves.
There is a broader honest point here. The independent literature on computerised cognitive training is genuinely mixed, particularly on whether gains generalise beyond the trained task. Anyone selling you certainty about that is selling you something. eMazeBrain's design bet is that clinician-directed targeting, prescribed dosing and visible adherence make a material difference compared with unsupervised consumer training — and that bet is exactly what the research underway is meant to test.
Four
Our standard of proof
So that you can hold us to it, here is the rule we have committed to for anything that ever appears on this page or anywhere else on this site.
Name the instrument
Any outcome figure states what was measured and on which instrument. “Improved attention” without an instrument is not a result.
Describe the population
Ages, diagnoses, presentation and how participants were selected. A result in one population is not a result in another.
State the sample and the design
How many, over how long, controlled or observational. Observational data will be labelled observational.
Link the source
The full study, not a summary of it, so you can form your own view of the methods.
If you find something on this site that does not meet that standard, tell us and we will remove it. drhish@emazelabs.com
See it running against your own caseload.
Twenty minutes, screen-shared, with a clinician who treats these children every week. Bring one patient you're stuck on and we'll build the program live.
Or email drhish@emazelabs.com · WhatsApp +972 50 834 2448